Zura Bio Q3 net loss widens on higher R&D costs

Overview

• US biotech firm's Q3 net loss widened to $25.8 mln, loss per share at $0.20

• Higher R&D expenses driven by ongoing Phase 2 tibulizumab studies and NEXUS-PMR start-up

• Company ended Q3 with $187.7 mln cash, expects runway through at least end of 2028

Outlook

• Company expects cash runway to fund operations through at least end of 2028

• Zura Bio expects TibuSHIELD topline data in HS in Q4 2026

• Company expects TibuSURE topline data in SSc in H1 2027

Result Drivers

• CLINICAL STUDY COSTS - Higher R&D expenses attributed to ongoing Phase 2 tibulizumab trials and NEXUS-PMR study start-up

• PROFESSIONAL FEES - Increased G&A expenses due to higher professional fees

• FULL ENROLLMENT - Company completed enrollment for Phase 2 tibulizumab studies in HS and SSc, exceeding targets

Company press release:

Key Details

Analyst Coverage

• The current average analyst rating on the shares is "strong buy" and the breakdown of recommendations is 8 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"

• The average consensus recommendation for the biotechnology & medical research peer group is "buy."

• Wall Street's median 12-month price target for Zura Bio Ltd is $19.00, about 433.7% above its October 26 closing price of $3.56

Reuters Recommended Reads

• Oct 26 - Aspen Neuroscience, Bambusa Therapeutics launch US IPOs as biotech boom rolls on

• Oct 26 - Acumen Pharmaceuticals posts smaller than expected Q3 loss

• Oct 27 - Nautilus Biotechnology Q3 revenue beats

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)